ProCE Banner Activity

Phase Ib Study of Gilteritinib Combined With Venetoclax for R/R Acute Myeloid Leukemia

Slideset Download
Conference Coverage
In patients with R/R FLT3-mutated AML, the combination of gilteritinib plus venetoclax was tolerable and efficacious, with no new safety signals.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation